Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:729725.
doi: 10.1155/2010/729725. Epub 2010 May 24.

Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies

Michael Medinger  1 , Natalie Fischer, Alexandar Tzankov
Affiliations

Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies

Michael Medinger et al. J Oncol. 2010.

Abstract

Angiogenesis is essential for malignant tumor growth. This has been documented for solid tumors, and there is an emerging evidence suggesting that tumor progression of hematolymphoid malignancies also depends on the induction of new blood vessel formation. The most important proangiogenic agent is vascular endothelial growth factor (VEGF), activating VEGF receptors 1 and 2. The available data on angiogenesis in hemato-lymphoid malignancies, such as acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and lymphomas, point towards the significance of autocrine and paracrine VEGF-mediated effects for proliferation and survival of leukemia/lymphoma cells in addition to tumor vascularization. Antiangiogenic strategies have become an important therapeutic modality for solid tumors. Several antiangiogenic agents targeting VEGF-related pathways are also being utilized in clinical trials for the treatment of hemato-lymphoid malignancies, and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hemato-lymphoid malignancies and the translation of such basic findings into clinical studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Possible vascular endothelial growth factor- (VEGF) and VEGF receptor-related (e.g., Flk-1, i.e., VEGFR-2) autocrine and paracrine loops in hemato-lymphoid neoplasms; insert: receptor tyrosine kinase activity and signaling cascades through VEGFR-2.
Figure 2
Figure 2
(a) Microvascular architecture in normal bone marrow highlighted by CD34; note single capillaries. (b) Increased microvessel density in acute myelogenous leukemia and in (c) myeloproliferative neoplasm; note dilated sinus and atypical megakaryocytes in the latter.
Figure 3
Figure 3
(a) Microvascular organization of the cortical (B-cell-) zone of a normal lymph node highlighted by CD34; note a perifollicular condensation of microvessels and paucity inside the follicle. (b) Increased microvessel density in a mantle cell lymphoma case; insert: vascular endothelial growth factor expression in a diffuse large B-cell lymphoma case highlighted by immunohistochemistry.
See this image and copyright information in PMC

References

    1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine. 1995;1(1):27–31. - PubMed
    1. Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine. 1971;285(21):1182–1186. - PubMed
    1. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine. 2001;7(11):1194–1201. - PubMed
    1. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Reviews Cancer. 2002;2(11):826–835. - PubMed
    1. Peters BA, Diaz LA, Jr., Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Medicine. 2005;11(3):261–262. - PubMed

LinkOut - more resources